

ASX Announcement

Monash IVF Group Limited (ASX: MVF)

13 April 2026

Revised non-binding indicative proposal to acquire Monash IVF

As previously announced to the market on 24 November 2025, Monash IVF Group Limited (ASX: MVF, the “**Company**” or “**Monash IVF**”) rejected an opportunistic, unsolicited, conditional and non-binding indicative proposal from a consortium comprising Genesis Capital Investment Management Pty Ltd (“**Genesis Capital**” or “**Genesis**”) and WHSP Holdings Pty Limited (“**Soul Patts**”) (together, the “**Consortium**” and each a “**Consortium Member**”) to acquire 100% of the shares in Monash IVF by way of a Scheme of Arrangement at \$0.80 per share. The Company has now received a revised, unsolicited, conditional and non-binding indicative proposal from the Consortium (“**Proposal**”).

The indicative cash price offered to shareholders under the Proposal is \$0.90 per share (“**Offer Price**”). The Proposal states that the Offer Price 'represents the highest amount the Consortium is prepared to offer as its Offer Price, absent a competing proposal emerging for all or a material part of Monash IVF.' The Proposal is also expressed to be 'valid until close of business on Tuesday, 21 April 2026'.

The Proposal is subject to a number of conditions, including:

- exclusive due diligence, including a 4 week period of exclusivity with no fiduciary exceptions;
- negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition;
- unanimous recommendation of the Monash IVF Board of the Proposal; and
- final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation.

As at 24 November 2025, the Consortium holds an interest in approximately 19.6% of the ordinary shares in Monash IVF.

The Monash IVF Board is assessing the Proposal, including obtaining advice from its financial and legal advisers.

Shareholders do not need to take any action in relation to the Proposal. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction.

Monash IVF has appointed Macquarie Capital as its financial adviser and Clayton Utz as its legal adviser.

If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations.

Authorised by the Board of Directors.

For further information please contact:

Rebecca Dean

General Counsel & Company Secretary

Monash IVF Group

T: +61 402 419 626

E: rebecca.dean@monashivfgroup.com

Media enquiries

GRACosway

Geoff Elliott

T: +61 488 051 888

E: gelliott@omc.com